AbbVie Inc. (ABBV)
| Market Cap | 396.55B |
| Revenue (ttm) | 59.64B |
| Net Income (ttm) | 2.35B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.32 |
| PE Ratio | 169.90 |
| Forward PE | 16.35 |
| Dividend | $6.92 (3.08%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 5,096,922 |
| Open | 224.82 |
| Previous Close | 225.11 |
| Day's Range | 223.11 - 226.63 |
| 52-Week Range | 164.39 - 244.81 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 240.12 (+7.02%) |
| Earnings Date | Oct 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $240.12, which is an increase of 7.02% from the latest price.
News
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of ...
2 Top Dividend Stocks to Buy Now and Hold For a Decade
Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues to grow its dividend through tough times.
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating
AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antib...
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
The stocks listed below yield between 2.7% and 3.5%. They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster inno...
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
5 Dividend Stocks to Hold for the Next 10 Years
These dividend stocks represent the communications services, energy, financial services, healthcare, and real estate sectors. All of them have attractive dividend yields.
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma aft...
It's Best Time In 10 Years To Lock In Income: Our Picks
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–8...
AbbVie Stock Falls 4% -- What Investors Need to Know
AbbVie's third-quarter results were pretty strong, and the company increased its guidance. It was not enough to impress the market, which apparently expected more from the drugmaker.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
AbbVie is a Dividend King with a bright future. Enbridge offers an especially dependable dividend.
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript
AbbVie Inc. ( ABBV) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena So...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small bu...
2 Strong Healthcare Stock Picks for Dividend Investors
These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products.
AbbVie Shares Rise To Intraday High After Key Trading Signal
AbbVie Inc (NYSE:ABBV) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail or...
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advanc...
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories ...
AbbVie Has Many Bullish Attributes (Technical Analysis)
AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and...
Three Healthcare Buys That Wall Street Loves
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
5 Top Stocks to Buy in November
As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all thi...